Avalo Therapeutics, Inc.

AVTX

NASDAQ

Healthcare

Biotechnology

Rockville, MD, US23 employeesavalotx.com

$17.79

+1.09(6.5%)

52W $3.59 – $19.95

AI-generated

Avalo Therapeutics, Inc.

Revenue breakdown: Product (100%).

$201MMkt Cap

-$176.1KRev TTM

-$66MNI TTM

-2.3xP/E TTM

Latest Earnings

10-K

FY FY2025Mar 22, 2026

Avalo Therapeutics, Inc. (AVTX) reported a net loss of $78.3 million for FY 2025, a $43.1 million increase from $35.1 million in FY 2024, driven by heightened research and development (R&D) expenses of $50.1 million (up $25.6 million YoY) tied to the Phase 2 LOTUS trial for lead candidate abdakibart (AVTX-009) in hidradenitis suppurativa (HS). Total revenues were minimal at...

Read full analysis View SEC Filing

What Changed Recently

Financial Results

Mar 22, 2026

(including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”) or o

View filing →

Financial Results

Jan 11, 2026

of this Current Report on Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amen

View filing →

View all recent events →

Fundamentals

How The Business Makes Money

Revenue by Segment

Product100%($900.0K)

Analyst View

Peer Companies

Company	Price	Change	Market Cap	P/E
ENTAEnanta Pharmaceuticals, I...	$13.15	+1.39%	$305M	-3.8
IVAInventiva S.A.	$5.48	+0.92%	$285M	-1.8
OBIOOrchestra BioMed Holdings...	$4.26	-1.81%	$249M	-3.5
EPRXEupraxia Pharmaceuticals ...	$7.18	-2.05%	$240M	-11.0
CHRSCoherus Oncology, Inc.	$1.72	-1.15%	$201M	-1.2
PRLDPrelude Therapeutics Inco...	$3.51	+1.74%	$196M	-2.0
CRBUCaribou Biosciences, Inc.	$1.94	-2.76%	$187M	-1.2
BDTXBlack Diamond Therapeutic...	$2.40	+3.22%	$138M	5.5

Company Profile

CIK0001534120

ISINUS05338F3064

CUSIP05338F108

Phone410 522 8707

Address540 Gaither Road, Rockville, MD, 20850, US

SEC EDGAR